To determine if insulin-like growth factor I (IGF-I) inhibits pulsatile growth hormone (GH) secretion in man, recombinant human IGF-I (rhIGF-I) was infused for 6 h at 10 ,ug * kg-' * hduring a euglycemic clamp in 10 normal men who were fasted for 32 h to enhance GH secretion. Saline alone was infused during an otherwise identical second admission as a control. As a result of rhIGF-I infusion, total and free IGF-I concentrations increased three-and fourfold, respectively. Mean GH concentrations fell from 6.3±1.6 to 0.59±0.07 ,g/liter after 120 min.
Introduction
Insulin-like growth factor I (IGF-I) ' is a 70-amino acid peptide that has 50% homology with proinsulin (1) . The primary function of IGF-I is to mediate some of the growth-promoting actions of growth hormone (GH), although it also has some insulin-like metabolic effects (2) . Plasma IGF-I, derived primarily from hepatic synthesis under regulation by GH, may function as a classical endocrine hormone to stimulate new bone formation and organ growth ( 1, 2) . Alternatively, IGF-I may promote growth by a paracrine action since IGF-I is synthesized in many nonhepatic tissues, including the epiphyseal growth plate ( 1, 2). IGF-I circulates bound to several binding proteins that prolong the plasma half-life of IGF-I and modulate its bioavailability and action (3) .
GH is secreted by the anterior pituitary gland in a pulsatile fashion under the regulation of two hypothalamic peptides: GH-releasing hormone (GHRH) stimulates GH synthesis and secretion whereas somatostatin inhibits GH release (4) . Studies in rats, sheep, and humans indicate that whereas GHRH is required for the initiation of GH pulses, the amplitude of GH pulses is modulated by somatostatin (5) (6) (7) . In humans, these interactions result in a pattern ofvolleys ofGH secretory pulses with intervening periods ofrelative secretory quiescence (8) . A role for IGF-I in the negative feedback regulation of GH secretion was first suggested by intracerebroventricular (ICV) injections of IGF preparations in rats that markedly diminished the amplitude of GH pulses in peripheral blood (9, 10) . These early IGF preparations may have contained both IGF-I and IGF-II since a combination ofboth recombinant human IGF-I (rhIGF-I) and IGF-II (rhIGF-II) was required to reproduce these observations in recent experiments ( 11) . In vitro, IGF-I decreases GH secretion and mRNA levels in cultured rat pituitary cells (12) . In studies with incubated rat hypothalami, IGF-I has been reported to increase somatostatin secretion ( 13, 14) and mRNA levels (14) ; GHRH release was increased in one study ( 14) and decreased in another ( 15 ) . In studies using the GH-deficient dwarf rat, ICV IGF-I infusions over 7 d increased somatostatin and decreased GHRH mRNA; this effect was not observed with systemic infusions ( 16) . Thus, in rats, IGF-I directly inhibits GH secretion by the pituitary gland and may also influence GH secretion via effects on the hypothalamus in combination with IGF-II.
Since many species differences in the regulation of GH secretion exist it is important to determine whether IGF-I inhibits GH secretion in man. Clinical investigations of rhIGF-I effects in man have focused primarily on its metabolic actions, although some information about its effect on GH secretion has been gleaned. Bolus injections ofrhIGF-I caused hypoglycemia and stimulated GH secretion ( 17 ) . However, ifhypoglycemia was avoided by food ingestion, then rhIGF-I infusions suppressed serum GH concentrations after 6 d in one of two subjects ( 18) and after 2 d in six subjects ( 19) . The timing and frequency of blood sampling in these studies was insufficient to assess the time course of effects of rhIGF-I on pulsatile GH secretion. Furthermore, subjects received mixed meals, which may have unpredictable effects on GH release since carbohydrates suppress and some amino acids stimulate GH release (4) . The purpose of this study was to investigate the effect of IGF-I on pulsatile GH secretion in man using methods that would circumvent the confounding factors identified in previous studies. We infused a low dose of rhIGF-I ( 10 jig* kg-' h'-) during a simultaneous euglycemic clamp (20) in subjects fasted for 32 h to increase GH secretion (21, 22) ; blood samples were obtained at 5-min intervals for 8 h and GH secretion rates were estimated by deconvolution analysis (23). We report that fasting-enhanced pulsatile GH secretion is rapidly suppressed by a low-dose rhIGF-I infusion, which stimulates minimal glucose uptake, suppresses insulin and glucagon levels rapidly, and has a delayed antilipolytic effect.
Methods
Subjects and study design
The study was approved by the Human Investigation and General Clinical Research Center Advisory Committees of the University of Virginia. 10 healthy men (ages 21-36 yr) of normal body weight (body mass indexes 20.8-26.6 kg/m2) were studied after written informed consent. All were nonsmokers, were taking no medications, had not undertaken transmeridian travel for > 4 wk. and had unremarkable clinical histories and physical examinations. All had normal biochemical indexes of renal, hepatic, and hematologic function and normal fasting serum concentrations of glucose, glycated hemoglobin, IGF-I, thyroxine (T4), thyroid stimulating hormone (TSH), prolactin, luteinizing hormone (LH), and follicle stimulating hormone (FSH). The subjects were studied on two occasions separated by 2 4 wk and took ferrous sulfate between study days. For each study, the subjects fasted for 40 h during which they ingested only water, potassium chloride (20 meq/d), and a multivitamin tablet. Compliance with the fast was monitored by daily weights and measurement of urine ketones. Daily blood samples (0800 hours) were obtained for complete blood count, serum chemistries, and hepatic enzymes to monitor for adverse effects of the fast. The studies were performed on day 2 ofthe fast (32-40 h of fasting). The subjects received infusions of rhIGF-I and 20% dextrose during the first admission and normal saline during the second admission.
Admission 1: rhIGF-I infusion with euglycemic clamp. At 0600 hours on day 2 ofthe fast, two intravenous cannulas were placed anterograde in an antecubital vein for the continuous infusions of test substances and retrograde in a wrist vein for blood sampling. The latter was kept patent by a slow saline infusion and the hand was kept in a heated box at 70°C to ensure arterialization ofvenous blood (20) . The rhIGF-I (Genentech, Inc., South San Francisco, CA) was prepared as a 0.19-mg/ml solution in normal saline. From 0800 to 1600 hours, arterialized venous blood samples for measurement of GH and glucose ( 1.5 ml) were obtained at 5-min intervals and samples (11.0 ml) for total and free IGF-I, insulin, glucagon, 3-hydroxybutyrate (BOH), acetoacetate (AcAc), and FFA concentrations were obtained every 15 min during the first hour of the infusion and every 30 min for the remainder of the infusion. All serum samples were frozen at either -20 or -70°C until analyzed. At 1000 hours (time = 0 min), a 5-min priming infusion (20 jgg* kg-' h-') followed by a continuous infusion (10 ig* kg-' * h-1) of rhIGF-I was started. Plasma glucose concentrations were maintained at basal levels by a variable 20% dextrose infusion that was adjusted every 5 min on the basis ofplasma glucose measurements and a negative feedback algorithm (20) . The actual glucose concentration ofthe 20% dextrose solution was measured for each experiment. A glucose analyzer (Beckman Analytical System Group, Columbia, MD) was used to measure plasma glucose concentrations rapidly during the clamp. The infusions were delivered by microprocessor pumps (model 22; Harvard Apparatus, South Natick, MA) that were controlled by a computer program (running on an IBM-compatible computer) written and kindly supplied by Dr. David Krusch (University ofRochester, Rochester, NY). Subjects remained supine and awake during the study. The infusions and blood sampling were terminated at 1600 h and the subjects were fed. The subjects were observed overnight for possible delayed hypoglycemic effects of rhIGF-I. The dose of rhIGF-I was chosen to minimize the amount ofglucose infused to prevent hypoglycemia; previous investigators had fed subjects 2,500 kcal/d to avoid hypoglycemia during an infusion of20 ig* kg-' * h-' ( 18 ) . The rhIGF-I infusion and euglycemic clamp were continued for 6 h to optimize our observations of effects on pulsatile GH secretion.
Admission 2: saline infusion. As a control, the subjects were studied on a second occasion using the same protocol as Admission 1 except that an infusion of normal saline, matched to the volume of the previous 20% dextrose and rhIGF-I infusions, was administered. The subjects were fed at 1600 hours and then discharged.
Assays
Growth hormone. Serum GH concentrations were measured in duplicate by immunoradiometric assay using standards diluted in human serum (Nichols Institute, San Juan Capistrano, CA). The sensitivity of the assay was 0.2 jig/liter; samples with < 0.2 jg/liter GH were set equal to 0.2 jg/liter for statistical analyses. The mean intra-and interassay coefficients of variation (CV) were 8.4 and 8.0%, respectively. Total and free IGF-I. Total plasma IGF-I was measured by RIA after acid ethanol extraction. The concentration offree IGF-I in plasma was measured by RIA after size-exclusion chromatography. These methods, previously published in brief form (24) , are described in detail here.
Acid ethanol extraction for total IGF-I quantitation. To dissociate IGF-I from IGF-binding proteins (IGFBP) before RIA, plasma samples were extracted with acid ethanol according to a modification ofthe method of Daughaday et al. (25) . One part plasma sample was mixed with four parts acid ethanol ( 12.5% 2 N HCI, 87.5% ethanol, 200 proof) and allowed to incubate on ice for 30 min. The samples were then microcentrifuged for 5 min in a Fisher microfuge model 235C; (Fisher Scientific Co., Pittsburgh, PA); the supernatant was removed and neutralized by adding one part of 1 M Tris base buffer, pH 9.5, to five parts of supernatant. These samples were then diluted 1:10 in the assay diluent described below for RIA. The recovery of IGF-I in the RIA after acid ethanol extraction was > 80%.
Chromatographic separation offree IGF-I. Size-exclusion HPLC (SE-HPLC) was used to separate free IGF-I from IGF-I complexed with binding proteins; a 2.5 x 30 cm TSK-G2000SW column (HPGenenchem, South San Francisco, CA) and a mobile phase of0.2 M sodium phosphate, 0.05% polysorbate (Tween) 20 (Sigma Chemical Co., St. Louis, MO), pH 6.5 was used. Samples were prefiltered using a 25-mm diameter, 0.22-jim, Millex-GV filter (Millipore Corp., Bedford, MA) and for some samples a 7.5 x 75 mm silica guard column (Bio-Rad Laboratories, Richmond, CA) was used to reduce the effects of plasma proteins on the performance of the TSK-G2000SW column over time. The sample injection volume was 100 jl and a flow rate of 1 ml/min was used. The HPLC system used was an isocratic pump system (series 410 Perkin Elmer Corp., Norwalk, CT) equipped with an automatic sample injection system. Fractions were collected (0.5 ml) between 11 and 14 min after sample injection using a fraction collector (Foxy 200; Isco, Lincoln, NE). At the flow rate of 1 ml/min, this was the time that corresponded to the elution of proteins with molecular masses between 17 (myoglobin) and 1.4 kD (vitamin B-12), using the low molecular weight markers from Bio-Rad Laboratories. After chromatography, IGF-I concentrations were measured by RIA in the fractions where standard IGF-I would elute. The sum ofthe concentrations of IGF-I in these fractions was considered to be the free IGF-I concentration for a given sample. Fractions with undetectable quantities of IGF-I were set equal to the assay sensitivity. The dissociation of the most abundant IGF-I-IGFBP complexes by this method was shown to be negligible using recombinant IGF-I-IGFBP-3 complexes. The recovery of rhIGF-I added to plasma was expected to vary with the concentration of rhIGF-I and between individuals because of the presence of IGFBPs in plasma. For plasma samples containing 100, 250, and 500 jig/liter added rhIGF-I, the percent recovered as free IGF-I averaged 51, 71, and 80%, respectively; this suggests increasing saturation of binding sites at the higher concentrations.
IGF-I RIA. For RIA, samples or standards (rhIGF-I) were diluted in an assay diluent consisting ofPBS containing 0.1% gelatin (Eastman Kodak Co., Rochester, NY), 0.05% polysorbate (Tween) 20 (Sigma Chemical Co.) and 0.01% thimerosal (Sigma Chemical Co.). After addition of '251I-IGF-I tracer and a rabbit anti-human IGF-I antibody (provided by Peter Gluckman, Auckland, New Zealand), the tubes were incubated overnight at 2-80C; goat anti-rabbit IgG immunobeads (Bio-Rad Laboratories) were then added. A gamma counter (model 28023; Micromedic Systems Inc., Horsham, PA) with accompanying four-parameter curve-fitting software (version 1.51 ) was used to determine the sample values. For total IGF-I measurement (extraction + RIA), intra-and interassay CVs ranged from 2.4 to 7.0% and 12 to 19%, respectively, for concentrations between 98 and 166 jg/liter. Cross-reactivities of human IGF-II and insulin were 0.25 and 0.08%, respectively. The sensitivity of this assay was 0.3 jg/liter. The normal range for men aged 18-35 after an overnight fast in this assay is jg/liter (mean±SD: 132±49 jg/liter, n = 76; Genentech, Inc., unpublished observations). For free IGF-I measurement (SE-HPLC + RIA), interassay CVs were 6 and 17% for samples with mean recovered free IGF-I concentrations of 178 and 51 jg/liter, respectively. The sensitivity ofthis assay was 1.6 jg/liter; samples with < 1.6 Ag/liter free IGF-I were set equal to 1.6 jg/liter for statistical analyses. In previous studies, the vast majority of men aged 18-35 had undetectable free IGF-I concentrations after an overnight fast (reference 24 and Genentech, Inc., unpublished observations).
Other assays. Plasma insulin was measured by an RIA method with a sensitivity of 11 pmol/L (26); the interassay CV was 11% at 49 pmol/L and 5.9% at 100 pmol/L. Plasma glucagon was measured by RIA after acetone extraction (27) ; the sensitivity of the assay was 10 ng/L and the interassay CV was 12% at 44 ng/L and 21% at 19 ng/L. This glucagon assay excludes "big plasma glucagon," which is not pancreatic in origin (27) . Samples with undetectable amounts ofthe above hormones were assigned the value of the sensitivity of the assay for statistical analysis. Previously described methods were used to measure FFA, BOH, AcAc, prolactin, LH, and FSH (28) (29) (30) . Hematology, serum chemistry, glycated hemoglobin, T4, and TSH measurements were performed in the Clinical Laboratories of the University of Virginia Health Sciences Center using routine methods.
Deconvolution analysis ofGH secretion
A waveform-independent deconvolution method was used to estimate endogenous GH secretion rates from the serial serum GH concentrations. This method, previously described in detail, calculates hormone secretion rates at each time point, given an estimated hormone t1/2 and its associated variance, without making any assumptions about the nature of underlying hormone secretory events (23 
Group exponential analysis ofGH secretion rates
To estimate the 1/2 of suppression of GH secretion rates by rhIGF-I, deconvolution-resolved GH secretion rates were modeled as an exponential decay starting at 1000 hours (the starting time ofthe infusions). The serial GH secretion rates for all 10 subjects were individually fitted to a general exponential function, F(t) = B + Ae(-A), where F(t) is the GH secretion rate at time t, B is the baseline to which the function decays exponentially, A is the amplitude, and k is the rate constant. Since the amount of GH secreted varied among subjects, A was resolved for each individual data set. However, since we desired to determine a weighted mean for k and B, these variables were constrained to be constant for all 10 data sets. The estimation of these parameters, along with their associated 95% confidence limits, was carried out by nonlinear, least-squares iterative curve fitting, assuming asymmetric partially correlated joint parameter variance spaces, as described earlier (32) . Parameter estimation was carried out using a modified GaussNewton quadratic convergence algorithm, in which the GH secretion rates were weighted inversely by the SD of the secretion rate at each 5-min interval, as resolved by deconvolution analysis (23). The group exponential fit was considered significant ifthe disappearance rate constant, k, was significantly different from zero and ifthe group ofamplitudes had a distribution of Z scores (A/SD) that was nonrandom by the Kolmogorov-Smirnov test (33) .
Statistical analysis
Results are expressed as means±SE. Since each subject served as his own control, paired comparisons between the results from the rhIGF-I and saline treatment days or between the baseline period and infusion period were made with the Wilcoxon signed rank test (33) . When groups had unequal numbers of samples because of missing data, the Wilcoxon rank sum test was used for unpaired comparisons (33) . All hypothesis testing was two sided. Statistical significance was assumed when P c 0.05, except where multiple comparisons were involved. In the latter case, the overall per study error rate was limited by restricting the per comparison P value to < 0.01, as suggested by recent statistical reviews of this issue (34) . However, when multiple comparisons were made over time, a P of < 0.05 was accepted if a clear trend towards increasing statistical significance over time was evident (34).
Results
Total andfree IGF-I concentrations. Baseline serum concentrations of total and free IGF-I on day 1 ofboth admissions (after an 8-h overnight fast) were 96±10 and 2.2±0.25 jug/liter, respectively. These values were unchanged by an additional 24 h of fasting (95±5.9 and 2.3±0. 28 ,jg/liter, respectively). Fig. 1 illustrates the changes in total and free IGF-I levels during the saline and rhIGF-I infusions. Total IGF-I concentrations during rhIGF-I infusion first became significantly different from those during saline infusion at 30 min (123±13 vs. 89±4.8 jg/liter, P < 0.05). Thereafter, total IGF-I levels gradually increased to 300 jg/liter after 300-360 min. During the baseline period (0800-1000 hours), free IGF-I concentrations were below the limit ofassay sensitivity ( 1.6 ,umol * kg-' * min' or 1.2±0.15 mg * kg-' -min' ).
GH concentrations and secretion rates. Individual serum GH concentrations during the 2-h baseline period and the 6-h infusions of saline and rhIGF-I are shown in Fig. 3 . During the baseline periods, GH concentrations were elevated as would be expected in subjects fasted for 32 h. Random pulses of GH secretion were evident before and during both infusions. However, in all 10 subjects GH concentrations were lower during the last 4 h of rhIGF-I infusion than during saline. Mean GH concentrations and deconvolution-resolved secretion rates are depicted in Fig. 4 . Mean GH concentrations fell from 6.3±1.6
to 0.59±0.07 sg/liter during the first 120 min of the rhIGF-I infusion. After 120 min, mean GH concentrations remained < 0.6 ,gg/liter, although small pulses of GH secretion were observed in eight subjects. Maximal GH concentrations after 120 min of rhIGF-I did not exceed 1 jug/liter in six subjects; two subjects had GH peak values of 2-3 Ag/liter (Fig. 3) the first 60 min of the rhIGF-I infusion. Fig. 5 illustrates 10 exponential decay curves fit to the individual GH secretion rates during the rhIGF-I infusion. This analysis revealed that GH secretion rates were suppressed by rhIGF-I with a tl2 of 16.6 min (67% confidence limits: 13.7-20.6 min). It was not possible to fit exponential curves to the GH secretion rates during saline infusion since the disappearance rate constant approached zero. Thus, infusion of saline had no effect on GH secretion. As shown in Fig. 6 , rhIGF-I reduced mean GH secretion rates fivefold during the 6-h period compared with saline There were no significant differences between pretreatment baseline periods for saline and rhIGF-I study days. Total and free IGF-I levels did not differ between subjects who had a decrease in the number of GH pulses and those who did not. GH secretion rates during the last 4 h of the rhIGF-I infusion were not correlated with total or free IGF-I concentrations. Insulin and glucagon concentrations. Changes in insulin and glucagon concentrations during the rhIGF-I and saline infusions are shown in Fig. 7 shown in Fig. 8 . During the first 3 h of saline and rhIGF-I infusions, FFA, BOH, and AcAc levels increased with no significant differences between the two infusions. However, after this time point FFA, BOH, and AcAc concentrations decreased for the remainder of rhIGF-I infusion whereas these levels continued to increase during the saline. Differences between the concentrations on rhIGF-I and saline days first became significant (P < 0.05) by Wilcoxon signed rank test at 210 min for FFA, 270 min for BOH, and 300 min for AcAc; these differences became progressively more significant by the end of the infusions (P < 0.01).
Adverse effects offasting and rhIGF-L Serum concentrations of uric acid, creatinine, and bilirubin increased, and bicarbonate and glucose decreased during the 2-d fast as previously observed (22) . A mild, reversible increase in serum transaminases occurred with fasting in one subject. The subjects experienced no adverse clinical effects from the rhIGF-I infusions. Small, asymptomatic decreases in plasma glucose concentrations (0.25-0.50 mmol/L) were observed in some subjects 30 min after discontinuing the rhIGF-I and glucose infusions. Thereafter, plasma glucose concentrations increased as the subjects were fed. No hypoglycemia occurred in overnight monitoring after the rhIGF-I infusions.
Discussion
This study demonstrates that fasting-enhanced pulsatile GH secretion in man is rapidly suppressed by a low-dose infusion of 2458 .2.
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INFUSION TIME (I rhIGF-I when euglycemia is maintained. Deconvolution-resolved GH secretion rates decreased with a t,12 of -17 min after the start of the rhIGF-I infusion. By 60 min GH secretion rates were suppressed and remained so with only infrequent small pulses of secretion thereafter. Our exponential decay model likely overestimated the time to cellular response to rhIGF-I because: (a) free IGF-I concentrations were rising during the first hour ofthe infusion; (b) subpopulations of somatotrophs are differentially responsive to IGF-I (35); and (c) concurrent concentrations ofGHRH and somatostatin modify the effect of IGF-I on GH secretion (36) (37) (38) . Nevertheless, these studies establish that the negative feedback effects of rhIGF-I on GH secretion occurs within minutes in man. The predominant effect of rhIGF-I on pulsatile GH secretion was to decrease the mass of GH secreted per pulse. Although the number of detectable GH pulses was also decreased by rhIGF-I, we cannot be certain that IGF-I regulates GH pulse frequency since serum GH concentrations below the limit of our immunoassay have been shown to be pulsatile in ultrasensitive GH assays (39) . A primary effect of IGF-I on GH pulse amplitude was also observed in rats after ICV injections (9, 10) . High concentrations of IGF-I receptors have been identified in the pituitary gland (40) as well as in the median eminence of the hypothalamus (41 ) . Thus, in man, rhIGF-I likely decreases GH pulse amplitudes by interacting with pituitary IGF-I receptors and decreasing the somatotroph response to endogenous GHRH ( 12, (36) (37) (38) . The effects of rhIGF-I on the hypothalamus are less clear from in vivo and in vitro studies with rats. Infusion of rhIGF-I may decrease GH pulse amplitudes by increasing hypothalamic somatostatin secretion ( 13, 14) , perhaps in combination with endogenous IGF-II ( 11), and by decreasing GHRH secretion ( 15) , although conflicting data on GHRH release have been reported (14, 15) . Since some small GH pulses were observed after initial suppression of GH secretion by rhIGF-I, it is likely that the GH response to endogenous GHRH was not completely blocked by this dose of rhIGF-I.
The rapid suppression of GH secretion rates was closely associated with the rise in freeIGF-I levels, suggesting that GH release was directly inhibited by binding of rhIGF-I to pituitary and/or hypothalamic IGF-I receptors ( 1 1-15, 35-38, 40, 41 ) .
Although it is possible that rhIGF-I suppressed GH secretion by reversing other fasting-induced hormonal and/or metabolic changes, this seems less likely in view ofthe known direct inhibitory effects of IGF-I on GH release in vitro (12, (35) (36) (37) (38) Several other investigators have infused rhIGF-I in humans to study its metabolic effects but we are aware of only two studies in which euglycemia was maintained and GH concentrations were measured (18, 19) . In both studies, GH was measured only after prolonged infusions and with insufficient frequency to assess effects on pulsatile GH secretion. After 6 d of rhIGF-I infusion, Guler and colleagues (18) demonstrated decreased GHRH-stimulated GH release in one of two subjects and decreased spontaneous nocturnal GH release in one subject. Zenobi and co-workers (19) found that serum GH levels were lower in single samples obtained after 24, 29 , and 33 h of rhIGF-I infusion compared with a saline control infusion. In the latter study, the differences were small since GH concentrations were also low on the saline control day ( 19) , as is expected in fed subjects during the daytime (8, 21, 22) . Our data extend these observations by demonstrating the rapid and profound inhibitory effects of IGF-I on pulsatile GH secretion under conditions in which this effect could be optimally observed.
The minimum dose of rhIGF-I necessary to suppress GH secretion is not known. In our study, continuous infusion of 10 ,ug * kg-' -h'-for 6 h increased total IGF-I concentrations from -100 to 300 ,ug/liter, which is slightly above the normal range for our assay (31-240 jtg/liter). Mean free IGF-I levels increased from 2.4±0.2 during the baseline period to 9.9±3. 5 ,gg/liter after 3 h of rhIGF-I infusion and then remained between 8 and 9.5 ,ug/liter for the remainder of the infusion.
However, GH secretion rates were suppressed within the first 60 min of the infusion when total and free IGF-I levels were 1.6-and 2-fold above baseline levels, respectively. In the study Suppression (19) . Other studies have achieved higher total and free IGF-I concentrations using higher doses of rhIGF-I administered either as continuous infusions (18, 43, 45) or boluses (17, 24, 46) . Thus, our study and that ofZenobi et al. (19) indicate that rhIGF-I infusions that increase total and free IGF-I levels two-to fourfold will suppress serum GH concentrations. Further studies will be required to determine if lower doses of rhIGF-I will suppress GH secretion. Although glucose was infused to maintain euglycemia in our fasted subjects, only minimal amounts were infused during the first 60 min when GH secretion rates were decreasing. The amount of glucose infused corresponded to an hourly glucose dose for a typical 70-kg man of0.7 and 5.0 g during the first and last hours of the rhIGF-I infusion, respectively. For the entire 6-h infusion, the total glucose dose was -20 g or 80 kcal, which is considerably less than the 2,400-2,500 kcal ingested to maintain euglycemia during the continuous rhIGF-I infusions performed by Guler et al. (18) and Zenobi et al. (19) . It is likely that glucose uptake was stimulated by rhIGF-I since plasma insulin concentrations were suppressed as previously reported (18, 19, 24, (45) (46) (47) . Furthermore, IGF-I receptors are present in human skeletal muscle and IGF-I stimulates muscle glucose uptake in vitro with a similar dose-response curve as insulin (48) . However, it is unlikely that glucose uptake was responsible for suppression of GH secretion since very little glucose was infused to maintain euglycemia during the first hour of the rhIGF-I infusion. In addition, preliminary data indicate that a low-dose euglycemic insulin infusion (steady state insulin concentrations 150 pmol/L or 21 uAU/ml) that stimulates twice as much glucose uptake as the present rhIGF-I infusion does not suppress spontaneous GH secretion during the first 4 h (49). Higher insulin levels ( 400 pmol/L) during euglycemic clamps resulted in variable suppression of the GH response to GHRH in five normal subjects, although this was not statistically significant (50) . Thus, it seems likely that inhibition of GH secretion and stimulation of glucose uptake are independent actions ofrhIGF-I and that lower doses ofrhIGF-I would suppress GH secretion without stimulating glucose uptake.
In addition to the rapid decreases in GH and insulin levels, plasma glucagon concentrations were rapidly suppressed by rhIGF-I (within 1-2 h). Similarly, Boulware and colleagues (47) reported a 40% decrease in glucagon concentrations during a 3-h euglycemic infusion of rhIGF-I in man. Since euglycemia was maintained by a glucose clamp it is unlikely that the glucose infusion inhibited glucagon release. High affinity IGF-I receptors have been identified on rat pancreatic alpha and beta cells (51) . In studies with human fetal islet cell clusters in tissue culture and rat pancreas perifusion systems, IGF-I acutely decreased insulin secretion but had no effect on glucagon release (52) (53) (54) . Thus, although it is likely that rhIGF-I has a direct inhibitory effect on beta cell insulin secretion, the mechanism by which rhIGF-I decreased glucagon concentrations is not known.
In rats, IGF-I infusions stimulated glucose uptake but had no effect on hepatic glucose production or circulating concentrations of lipid metabolites (55, 56) . This suggested that the metabolic effects of IGF-I are mediated by its own receptor and not the insulin receptor (2, 56 receptors cannot be excluded.
The mechanisms responsible for enhanced GH secretion with fasting are not known. Since prolonged fasting decreases total IGF-I concentrations (59), a reduction in negative feedback on GH is possible. However, in this study and in our previous studies (21, 22) , increases in pulsatile GH secretion occurred before significant decreases in total IGF-I levels. Of interest, the time course of suppression of fasting-enhanced GH secretion by rhIGF-I is virtually identical to that of refeeding with balanced eucaloric meals (60) . This suggests that similar changes in free IGF-I occur in both experimental paradigms. Since IGFBP-1 concentrations are increased by fasting and decrease rapidly after refeeding (3, 59) , rapid changes in IGFBP-1 concentrations may mediate the effects of nutrition on GH secretion by altering the unbound concentrations of IGF-I.
In conclusion, fasting-enhanced GH secretion is rapidly suppressed by a low-dose euglycemic IGF-I infusion that stimulates minimal glucose uptake while decreasing insulin and glucagon levels. The predominant effect ofIGF-I is to decrease the mass of GH secreted per secretory pulse. Delayed suppression of lipid metabolites may reflect decreases in GH and glucagon concentrations or a direct effect of IGF-I. The rhIGF-I infusion suppressed fasting-enhanced GH secretion with a similar time course as refeeding, suggesting that changes in plasma concentrations of free IGF-I and/or IGFBPs mediate the effects of nutrition on GH secretion.
